ABSTRACT The covalent attachment of protein-resistant polymers to therapeutic proteins is a widely used method for extending their in vivo half-lives; however, the effect of molecular weight of polymer on the in vitro and in vivo functions of protein-polymer conjugates has not been well elucidated. Herein we report the effect of molecular weight of poly(oligo(ethylene glycol) methyl ether methacrylate) (POEGMA) on the in vitro and in vivo properties of C-terminal interferon-alpha (IFN)-POEGMA conjugates. Increasing the molecular weight of POEGMA decreased the in vitro activity of IFN-α but increased its thermal stability and in vivo pharmacokinetics. Intriguingly, the in vivo antitumor efficacy of IFN-α was increased by increasing the POEGMA molecular weight from ca. 20 to 60 kDa, but was not further increased by increasing the molecular weight of POEGMA from ca. 60 to 100 kDa due to the neutralization of the improved pharmacokinetics and the reduced in vitro activity. This finding offers a new viewpoint on the molecular size rationale for designing next-generation protein-polymer conjugates, which may benefit patients by reducing administration frequency and adverse reactions, and improving therapeutic efficacy.
Proteins are of great interest for the treatment of many diseases due to their characteristics of high specificity and activity. However, their widespread use is hampered by their rapid elimination from the circulation, potential immunogenicity and low stability [1] [2] [3] . The covalent conjugation of a protein-resistant polymer, typically poly(ethylene glycol) (PEG), to therapeutic proteins, named PEGylation, is a clinically successful strategy to address the above shortcomings. Nevertheless, PEGylation has two major problems: 1) PEG is typically attached to reactive residues of lysine, histidine and cysteine that are randomly distributed on the protein scaffold, so that the conjugate stoichiometry and the conjugation site are out of control and thus results in a heterogeneous product composed of positional isomers, and with reduced biological activity [4, 5] ; 2) the yield for PEGylation is generally low (usually < 10%) due to the reaction between two large macromolecules, so that the molecular weight of PEG applied in industry is limited to be 40 kDa in consideration of the yield [6] . For instance, recombinant human interferon-alpha (IFN-α), a potent inhibitor of viral replication and tumor cell growth, has been clinically used for the treatment of viral diseases and cancers, but it suffers from poor pharmacokinetics. To improve its pharmacokinetics, IFN-α is usually conjugated with 40 kDa branched PEG (PEGASYS) or 20 kDa linear PEG (PEGINTRON), but its activity is significantly reduced to 7% for PEGASYS [7] or 28% for PEGINTRON [8] . It is anticipated that the activity of protein-polymer conjugate can be well remained by site-specific conjugation at the sites that are distant from the protein's receptor interaction site, such as the C terminus of IFN-α [9] [10] [11] .
To date, the effect of molecular size of PEGylated proteins on the in vitro activity and in vivo pharmacokinetics has well been studied, in which increasing the PEG molecular weight decreased the in vitro activity but improved the in vivo pharmacokinetics [10] [11] [12] [13] [14] [15] [16] [17] . Nevertheless, the polymer molecular weight effect on the in vivo therapeutic potential has rarely been reported in the literature [10, 15, 17] , and the preliminary conclusion is that increasing the PEG molecular weight enhanced the in vivo therapeutic efficacy. Unfortunately, the molecular weight of PEG was limited up to 40 kDa in these studies, so that the effect of higher molecular weight of PEG on the function of protein, particularly the in vivo therapeutic potential, has not been elucidated. Additionally, in most of these studies, PEG was randomly conjugated to a protein to yield a mixture of positional isomers, each with distinct in vitro activities, in vivo pharmacokinetic and therapeutic profiles, which further complicated and thus hampered these studies. Hence it is of great interest to synthesize site-specific protein-polymer conjugates with different high molecular weights of polymer to systemically study the effect of molecular size of polymer on the in vitro and in vivo properties of protein.
To this end, herein we report the effect of molecular weight of a PEG-like polymer, poly(oliga(ethylene glycol) methyl ether methacrylate) (POEGMA) on the in vitro activity and stability, in vivo pharmacokinetics and antitumor efficacy of C-terminal IFN-α conjugates of POEGMA. Most recently, we have demonstrated site-specific in situ growth (SIG) of a C-terminal IFN-α conjugate of POEGMA that outperforms PEGASYS in antitumor efficacy [18] . Inspired by this work, we chose to synthesize C-terminal IFN-α conjugates of POEGMA with three high molecular weights of ca. 20, 60 and 100 kDa by using the SIG method that has recently been developed by us [18] [19] [20] [21] [22] . We found that increasing the molecular weight of POEGMA decreased the in vitro activity of IFN-α but increased the in vitro stability of IFN-α. In a mouse model, the pharmacokinetics of IFN-α was enhanced by increasing the molecular weight of POEGMA. Interestingly, in a tumor-bearing mouse model, the antitumor efficacy of IFN-α was improved by increasing the POEGMA molecular weight from 20 to 60 kDa, but was not further enhanced by increasing the POEGMA molecular weight from 60 to 100 kDa. To our knowledge, this finding has not been reported in the literature yet.
To synthesize C-terminal IFN-POEGMA conjugates, a triglycine-functionalized initiator for atom transfer radical polymerization (ATRP) was solely attached to the C-terminus of recombinant IFN-α by sortase A mediated ligation to yield a C-terminal IFN-α-initiator conjugate (IFN-Br) [18] . Subsequently, in situ ATRP of OEGMA from IFN-Br was performed to yield C-terminal IFN-POEGMA conjugates (Fig. 1a) . Based on our previous work in which a C-terminal IFN-POEGMA conjugate with the POEGMA molecular weight of 66.2 kDa outperforms PEGASYS in antitumor efficacy [18] , we chose to synthesize three C-terminal IFN-POEGMA conjugates with POEGMA molecular weights that were below, near and above 66.2 kDa. The molecular weight of POEGMA was controlled by adjusting the feeding molar ratio of OEGMA to IFN-Br. After these in situ ATRP reactions, the ATRP solutions were directly analyzed by gel permeation chromatography (GPC) (Fig. 1b) . New GPC peaks corresponding to these IFN-POEGMA conjugates appeared at lower elution times of 19.5, 21.1 and 21.9 min than that (30.3 min) for IFN-Br while the GPC peak intensity of IFN-Br decreased, suggesting that the successful in situ growth of the IFN-POEGMA conjugates with different molecular weights, as expected. This result was confirmed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) (Fig. S1 , in Supplementary information), which revealed the appearance of new larger molecular weight bands corresponding to the IFN-POEGMA conjugates than that of the band for IFN-Br and simultaneously the decrease of the intensity of the band for IFN-Br. The IFN-POEGMA conjugates were purified by anion exchange chromatography (AEX). GPC traces showed the single peaks for the IFN-POEGMA conjugates without the peak for unreacted IFN-Br (Fig.  1c) , demonstrating the successful purification of the IFN-POEGMA conjugates by AEX. This result was also confirmed by SDS-PAGE (Fig. S2) , which displayed the bands for the IFN-POEGMA conjugates and the disappearance of the band for the unreacted IFN-Br.
To determine the molecular weights of POEGMA in the IFN-POEGMA conjugates, the IFN part of the conjugates was selectively digested with proteinase K and the remained POEGMA chains were then analyzed by GPC (Fig. S3) . The POEGMA molecular weight parameters and the overall yields of the three IFN-POEGMA conjugates were summarized in Table 1 . Based on the molecular weights of POEGMA, herein we name the three IFN-POEGMA conjugates as IFN-POEGMA 20, 60 and 100 kDa, respectively. Interestingly, the overall yield of IFN-POEGMA increased with the molecular weight of POEGMA, due to the less loss for IFN-POEGMA with the higher molecular weight of POEGMA during the conjugate purification process. The hydrodynamic radius (Rh) values of the conjugates determined by dynamic light scattering (DLS) were 5.9, 10.3 and 15.2 nm, respectively, which were 2.7-, 4.8-and 6.9-fold larger than that (2.2 nm) of IFN-α (Fig. 1d) . The secondary structural conformations of the conjugates were studied by circular dichroism (CD) (Fig. 1e) . The CD spectra of them showed a similar doublet at 208/222 nm that matched with that of IFN-α, suggesting that the in situ growth of POEGMA with different molecular weights from IFN did IFN-α is a highly pleiotropic cytokine, which is widely used to treat a variety of viral diseases and cancers [18, [23] [24] [25] . We investigated the antiproliferative activity of the conjugates using Daudi B cells (Fig. 2a) . The half maximal inhibitory concentrations (IC50's) of IFN-POEGMA 20, 60 and 100 kDa were 17.2, 31.2 and 51.4 pg mL −1 , respectively, which indicated 73.1%, 40.4% and 24.5% relative activities of that of IFN-α (IC50: 12.6 pg mL −1 ), respectively. These data indicated that increasing the molecular weight of POEGMA reduced the activity of IFN (Fig. 2b) , which could be attributed to the molecular weight dependence of the physical shielding effect of polymer on the function of protein.
IFN-α is thermally unstable since its antiproliferative activity rapidly decreased to nearly zero after incubation for 1 h at 50°C (Fig. 2c) . All of the IFN-POEGMA conjugates showed slower activity decreases than IFN-α, indicating that the POEGMA conjugation could improve the thermal stability of IFN. Additionally, IFN-POEGMA 60 kDa showed a much less activity decrease than IFN-POEGMA 20 kDa. Particularly, the relative activity of IFN-POEGMA 60 kDa was 62% after incubation for 4 h at 50°C, which was 248-fold higher than that (0.25%) of IFN-POEGMA 20 kDa. IFN-POEGMA 100 kDa also showed a slower activity decrease than IFN-POEGMA 60 kDa. These data indicated that increasing the molecular weight of POEGMA could increase the thermal stability of IFN. This result was further supported by CD analysis (Fig. 2d) . After incubation for 24 h at 50°C, all of the conjugates showed higher intensities of the doublet at 208/222 nm than IFN-α, indicating the higher α-helical structure retention of the conjugates than IFN-α. Furthermore, increasing the molecular weight of POEGMA improved the α-helical structure retention of IFN, as indicated by the higher intensity of the doublet of the conjugate with the higher molecular weight of POEGMA. Taken together, these data indicated that increasing the molecular weight of POEGMA could improve the thermal stability of IFN in activity and structure.
Next, we studied the in vivo properties of the IFN-POEGMA conjugates in mouse models. At first, we evaluated the pharmacokinetics of the conjugates by analyzing the plasma samples at various time points after their intravenous injection (Fig. 3a) . A two-compartment model was used to fit the data and the representative pharmacokinetic parameters of the conjugates and IFN-α were summarized in Table S1 . IFN-α was rapidly cleared from plasma with a high central clearance rate of 3.98 L h −1 kg −1 , and exhibited a short distribution half-life (t1/2α = 0.44 h) and terminal half-life (t1/2β = 1.52 h). This rapid clearance is because IFN-α has a small size of 2.2 nm in Rh that is much smaller than the effective size cutoff of kidney (ca. 5 nm in Rh [11] ). In contrast, the distribution half-lives (t1/2α = 9.4, 28.3 and 34.1 h) of the conjugates were increased by 21.4, 64.4 and 77.4 times as compared to that of IFN-α, respectively, and the terminal half-lives (t1/2β = 30.4, 48.1 and 62.8 h) of the conjugates were prolonged by 20.0, 31.6 and 41.3 times relative to IFN-α , respectively (Fig. 3b) . The central clearance rate of the IFN-POEGMA 20, 60 and 100 kDa conjugates decreased to 0.03, 0.02 and 0.01 L h −1 kg −1 , respectively (Fig.  3c) . This reduced clearance could be attributed to the increased hydrodynamic sizes (5.9, 10.3 and 15.2 nm in Rh) of the IFN-POEGMA conjugates that were well above the effective size cutoff of kidney. The differences in pharmacokinetics resulted in 85.1-, 166.6-and 238.6-fold increases in the area under the curve (AUC) of the conjugates (58.7, 114.9 and 164.6 mg L −1 h) relative to that of IFN-α (0.69 mg L −1 h), respectively (Fig. 3c) , indicating that increasing the POEGMA molecular weight improved the plasma exposure of IFN. Taken together, these data showed that increasing the molecular weight of POEGMA could enhance the pharmacokinetics of IFN-α due to the increased hydrodynamic sizes of the conjugates with the increased molecular weights of POEGMA.
To investigate the in vivo antitumor efficacy of the IFN-POEGMA conjugates (Fig. 4) , we treated nude mice bearing ovarian tumors of 20 mm 3 with the conjugates (20 μg IFN Equiv/mouse, weekly) until the tumors in all the control groups grew up to 500 mm 3 (Fig. 4a) . IFN-α did not show obvious inhibition on tumor growth relative to the negative control of saline. In contrast, IFN-POEGMA 20 kDa significantly inhibited tumor growth. Interestingly, IFN-POEGMA 60 kDa showed the same antitumor efficacy as IFN-POEGMA 100 kDa, as indicated by their complete inhibition on tumor growth. These results were related to animal survival after treatment (Fig. 4b) . The median survival time (42 days) for the mice treated with IFN-α was almost similar to that (38 days) for the mice treated with saline. In contrast, the median survival time (77 days) for the mice treated with IFN-POEGMA 20 kDa was 1.83-fold longer than that (42 days) for the mice treated with IFN-α. Particularly, the median survival times for the mice treated with IFN-POEGMA 60 and 100 kDa were not available as 75% mice in each group were tumor-free. The antitumor efficacy of the conjugates was verified by hematoxylin and eosin (H&E) staining of the tumors (Fig. 4c) . The tumors of the mice treated with saline and IFN-α showed closely-packed tumor cells with intact structure, while the tumors of the mice treated with IFN-POEGMA 20 kDa showed vacuolization, indicating that IFN-POEGMA 20 kDa caused damage to tumor cells. As expected, IFN-POEGMA 60 and 100 kDa induced severe damage to tumor cells, as indicated by the extensive vacuolization. Taken together, IFN-POEGMA 60 kDa showed better antitumor efficacy than IFN-POEGMA 20 kDa, while IFN-POEGMA 100 kDa showed similar antitumor efficacy to IFN-POEGMA 60 kDa. Considering that the AUC of IFN-POEGMA 100 kDa was 1.4-fold higher than that of IFN-POEGMA 60 kDa (164.6 vs. 114.9 mg L −1 h), whereas the in vitro antiproliferative activity (24.5% retention) of IFN-POEGMA 100 kDa was 1.6-fold lower than that (40.4% retention) of IFN-POEGMA 100 kDa, we think that the improved in vivo pharmacokinetics was offset by the reduced in vitro activity, which resulted in the similar antitumor efficacy. It should be pointed out that while the ovarian tumor model successfully demonstrated the in vivo antitumor effect of IFN-α and its polymer conjugates, no inhibitory effect was observed for ovarian carcinoma cells (OVCAR-3) in in vivo antiproliferative test. This indicates a complicated mechanism for the in vitro and in vivo antitumor effect, and more investigations are needed in order to better understand how the IFN-α inhibits tumor growth.
We also examined the biosafety of the conjugates. No loss of body weight was found for the mice treated with the conjugates and IFN-α (Fig. S4) . No apparent histological changes in major organs of heart, liver and kidney were observed after H&E staining of the organs of the mice treated with the conjugates, IFN-α and saline (Fig. S5 ). There were no significant changes in blood biochemistry parameters related to heart, liver and kidney function markers for the mice treated with the conjugates, IFN-α and saline (Fig.  S6) . The major hematological indicators such as red and white blood cells, platelets and hemoglobin for the mice treated with the conjugates and IFN-α appeared to be normal relative to those for the mice treated with saline (Fig.  S7) . These results indicated that increasing the molecular weight of POEGMA did not induce the systemic toxicity of IFN.
In conclusion, we report the effect of molecular weight of POEGMA on the in vitro and in vivo properties of C-terminal IFN-POEGMA conjugates. These conjugates with defined molecular weights of POEGMA were synthesized by the SIG method developed by us, which made it possible to systemically study the polymer molecular weight effect on the in vitro and in vivo properties of protein-polymer conjugates. This study leads to three major findings that are important for the design of advanced protein-polymer conjugates for disease treatment: (i) increasing the polymer molecular weight decreases the in vitro activity of the protein but improves the thermal stability of the protein, due to the molecular weight dependence of the physical shielding of polymer on the function of protein; (ii) increasing the polymer molecular weight enhances the in vivo pharmacokinetics of the protein because of the enlarged hydrodynamic size; (iii) increasing the polymer molecular weight does not always enhance the therapeutic efficacy of the protein as the improved in vivo pharmacokinetics may be offset by the decreased in vitro activity, which has not been reported in the literature. We believe that this new finding is of considerable interest as a novel molecular size rationale for the design of a number of next-generation protein/peptide-polymer conjugates for the treatment of various diseases.
